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Abstract
Previous research suggests that a co-morbid relationship exists between migraine and endometriosis; however, results have
been inconsistent. In addition, female hormones, which are important in the pathogenesis and management of
endometriosis, have been reported to precipitate migraine attacks and may confound the results. The aim of this
population-based cohort study was to explore the relationship between migraine and endometriosis in women of
reproductive age (18–51 years). Data were derived from the National Health Insurance Research Database of Taiwan, which
contains outpatient and inpatient records from 2000 to 2007. Our study cohort included 20,220 endometriosis patients and
263,767 controls without endometriosis. We analyzed the prevalence of migraine in these women as recorded during the
eight years of the database. Our results found that patients with endometriosis were more likely to suffer migraine
headaches compared to controls (odds ratio [OR], 1.70; 95% confidence interval [CI] [1.59, 1.82]; p,0.001). In addition, the
co-morbid association between migraine and endometriosis remained significant after the data were controlled for age and
frequently utilized hormone therapies (OR, 1.37; 95% CI, [1.27, 1.47]; p,0.001). The results of this cohort study support the
existence of a co-morbid relationship between migraine and endometriosis, even after adjusting for the possible effects of
female hormone therapies on migraine attacks.
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Introduction
Endometriosis is a gynecological disorder defined by the
presence of viable, extrauterine, endometrial tissue. This tissue
arises only in women of menstrual age, can grow or bleed
cyclically, and may cause adhesions. Typical symptoms include
pelvic pain, dysmenorrhea, and infertility [1]. Endometriosis
affects 6–10% of women of reproductive age, 50–60% of women
and teenage girls with pelvic pain, and up to 50% of women with
infertility [2].
Migraine is a neurological disorder that also commonly occurs
in women of reproductive age. An important advance in the
standardization of migraine diagnosis was the publication of
operational criteria by the Headache Classification Committee of
the International Headache Society (IHS) in 1988 [3]. Physicians
diagnose migraine according to the clinical symptoms. Migraines
typically present as recurrent episodic headaches and frequently
have the following pain characteristics: a unilateral location, a
pulsating quality, moderate-to-severe intensity, and aggravation by
routine physical activity. In addition, the attacks may be associated
with nausea, photophobia, or phonophobia symptoms.
Endometriosis and migraine share many similarities in epide-
miology, pathogenesis, and the physical or psychiatric co-
morbidities that can accompany them [4,5,6,7,8]. For example,
early menarche, a well-known risk factor for endometriosis, is also
associated with an increased risk of migraine [9]. Similarly,
menorrhagia, a frequent complaint of women with endometriosis,
is also common in women with migraine, with 63% of migraine
patients reporting a recent history of menorrhagia, compared to
37% of controls [10]. In addition, migraine patients with
endometriosis are more likely to have mood and pain-related
disorders than migraine patients without endometriosis [11].
Men also suffer from migraines; however, both the age-adjusted
prevalence of migraine (among men 8% and among women 26%)
and age of onset for migraine (among men 20% in the first
decennium, and 23% in the second and third decennium; among
women 9% in the first decennium, 34% in the second, and 30% in
the third) differ significantly between men and women [12,13].
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Cycling female hormones are abundant in women of repro-
ductive age and are deficient in postmenopausal women. As
mentioned earlier, these hormones play a key role in the
development of endometriosis. Brandes provided evidence linking
estrogen to migraines [14], while Misakian et al. reported that
hormone therapy for postmenopausal women was associated with
an increased incidence of migraines [15]. Conventional oral
contraceptives can also exacerbate migraines [16,17], while drug-
induced menopause, which decreases female hormones, can
reduce migraine symptoms. Danazol, a well-known male hormone
analogue used frequently in the management of endometriosis, has
been successful in controlling cyclic migraine symptoms [18]. In a
similar vein, progestogen-only oral contraceptives can reduce the
frequency of migraine attacks [19]. Taken together, these data
suggest that endometriosis and migraines may have a co-morbid
relationship due to the association with female hormones.
Although several studies have supported a relationship between
endometriosis and migraines, conclusions regarding the associa-
tion remain unclear. For instance, Tietjen et al. reported that both
the frequency and the prevalence of endometriosis were higher in
women with migraines than in migraine-free controls [10,11], and
the prevalence of migraines has also been shown to be higher in
women with endometriosis than in controls [20]. Nyholt et al.
proposed that common genetic influences might underlie the co-
morbid relationship between the two diseases [21]. Despite these
suggestive data, a recent study by Karp et al. failed to find
evidence that migraine headaches were more common in women
with endometriosis than in women without the disease [22]. One
explanation for these disparate results may be the differences in the
size and scope of the study populations used in the various
analyses.
The goal of the present study was to explore the relationship
between endometriosis and migraines in women of reproductive
age. We hypothesized that the migraine prevalence would be
higher in women with endometriosis than in women without the
disease. To address previous confounding in the literature and to
overcome any potential limitations from sample size, we used a
large nationwide medical database to investigate the co-morbidity
between endometriosis and migraines. Since hormone therapy
may be more frequently used in endometriosis patients, we also
included information from the database regarding prescriptions
for commonly administered hormone regimes, which further
isolated the potential confounding effects of these drugs.
Materials and Methods
The National Health Insurance (NHI) program in Taiwan was
initiated in 1995. As of December 2010, it covered over 99% of
the population (23,074,487 beneficiaries) and contracted support
from almost all medical hospitals and clinics in Taiwan (25,031
institutions) [23]. In 2000, the NHI Bureau initiated a program to
construct the NHI Research Database (NHIRD), and to release
claims data for academic medical and pathological research.
Subsequently, the NHIRD has emerged as one of the largest
nationwide medical datasets in the world and has been used
extensively for many epidemiological studies. The current study
was based on the 2005 NHIRD, which contained the data of 1
million randomly selected patients that were representative of the
entire population with regard to age, sex, and insurance cost.
Specifically, the database included information regarding both
inpatient and outpatient medical claims, as well as prescription
records.
1. Subjects
The study population was first filtered for ambulatory and
inpatient NHIRD claims made between 2000 and 2007 by women
of reproductive age (18–51 years old). Disease diagnosis from the
database was coded according to the International Classification of
Disease, 9
th Revision, Clinical Modification (ICD-9 CM).
The case cohort consisted of outpatient, or admitted patients,
that had been diagnosed with diseases related to endometriosis by
physicians from obstetrics and gynecology departments (ICD-9
CM codes: 617.x). In the end, data from 20,220 endometriosis
cases and 263,767 control samples were collected. We also
analyzed patients with any ambulatory visits or inpatient record
with a diagnosis of migraine, with or without aura (codes: 346.0x,
346.1x, and 346.9x) during the same period.
2. Endometriosis symptoms and treatments
For each subject in the study cohort, we searched the database
for diagnoses and treatment records related to endometriosis. The
diagnosis of endometriosis was mainly based on the clinical
symptoms (i.e., dysmenorrhea, which was defined as pelvic pain
during, shortly before, or after menstrual periods) medical signs
(for example, focal pain or tenderness during pelvic examination),
and sometimes imaging (ultrasound) or serum CA125 evaluations
[2]. Only those diagnoses that had been made by physicians in
an obstetrics and gynecology department were recorded. The
diagnostic search criteria included diagnoses related to infertility
(ICD-9 CM codes 628.x) and pelvic pain (625.9 and 789.00).
Surgical treatments for endometriosis were also recorded,
including laparoscopy (ICD-9 CM codes 542.1), laparoscopic lysis
of peritoneal adhesions (545.1), laparoscopic oophorotomy (650.1),
laparoscopic diagnostic procedures related to ovaries (651.3 and
651.4), laparoscopic local excision or destruction of ovaries (652.3,
652.4, and 652.5), laparoscopic unilateral oophorectomy (653.1),
laparoscopic unilateral salpingo-oophorectomy (654.1), laparo-
scopic removal of the remaining ovary (655.4) and tube (656.4),
laparoscopic salpingo-oophoroplasty (657.6), and laparoscopic
lysis of adhesions to the ovary and fallopian tube (658.1).
Hormonal treatment commonly used for endometriosis man-
agement, including danazol, estrogen, and progestin, was also
recorded for each patient. We then analyzed the prescription
orders from each drug category for individual subjects.
3. Statistical analysis
Analyses were performed using SPSS 18.0 software for
Windows (SPSS Inc., Chicago, IL, USA). The chi-square test
and Student’s T-test were used to compare demographics and
clinical variables between endometriosis cases and controls.
Logistic regression evaluated the proportion of co-morbid
migraines that was related to endometriosis. Two multivariate
models were constructed to independently ascertain whether
endometriosis had a co-morbid association with migraines. One
model assessed this relationship while adjusting for the potential
influences of age, infertility, pelvic pain and laparoscopic surgical
treatments. The other model was designed to validate the
relationship between endometriosis and migraine while adjusting
for the potential effects of age and hormone therapies. The results
from each model were expressed as an odds ratio (OR) with
95% confidence interval (CI). All tests were two-tailed, and p
values,0.05 were considered significant.
Results
Table 1 summarizes the demographic characteristics of the
study population. It should be noted that the endometriosis group
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controls, the endometriosis patients had a higher incidence of both
infertility (14.9 vs. 4.8%, respectively; p,0.001) and pelvic pain
(43.0 vs. 25.7%, respectively; p,0.001). Also as expected, the
patients in the endometriosis group were more likely than the
controls to have undergone both laparoscopic surgeries (21.2 vs.
1.7%, respectively; p,0.001) and danazol treatment (9.2 vs. 0.6%,
respectively; p,0.001) for the disease. Patients in the endometri-
osis group were also treated more frequently with female
hormones than were the controls, regardless of the type of
hormone or its dosage format (respectively: estrogen cream, 1.8 vs.
0.4%; estrogen tablet, 35.6 vs. 20.7%; progestin injection, 28.7 vs.
19.5%; progestin tablet, 48.1 vs. 25.9%; all p,0.001).
Patients in the endometriosis group were more likely than the
controls to be diagnosed with migraine during the study interval
(985 endometriosis cases [4.9%] vs. 7,701 controls [2.9%],
OR=1.70, 95% CI [1.59, 1.82], p,0.001; Table 2). Among the
985 endometriosis patients suffering from co-morbid migraine, a
majority experienced migraines after their endometriosis diagnosis
(776 cases [78.8%]) rather than before their diagnosis (209 cases
[21.2%]). For those women who experienced migraines after their
endometriosis, the mean duration between the two was
1,4776953.6 days, compared to the mean duration of
4906410.5 days for migraine occurring before endometriosis. If
we considered only those migraines occurring near the time period
at which endometriosis was diagnosed (from 1 year before the
endometriosis diagnosis date to 1 year after the end date), a similar
temporal relationship would be observed (after vs. before: 68.5%
vs. 31.5%). We used the same strategy with a two-year period
(from 2 years before the endometriosis diagnosis date to 2 years
after the end date) and the temporal relationship was not affected
(after vs. before: 66.5% vs. 33.5%). As shown in Table 2, both
multivariate regression model 1 (OR=1.36, p,0.001) and model
2 (OR=1.37, p,0.001) independently displayed co-morbid
relationships between endometriosis and migraines.
Discussion
The results of this study indicated that migraines are 1.70 times
more common in women with endometriosis than in those without
the disease. This finding supports previous observations that
endometriosis and migraines share a number of symptoms and risk
factors. In addition, migraines were more frequently reported in
women experiencing pelvic pain, a common symptom of
endometriosis, than in women without pelvic pain (OR=1.88,
adjusting for endometriosis diagnoses). In a previous report, Karp
et al. concluded that pelvic pain was an independent predictor of
migraine [22]. Indeed, our data compliment this conclusion and
demonstrate that endometriosis is also an independent predictor of
migraine (OR=1.36; adjusting diagnoses of pelvic pain).
A majority of the women experienced migraines after their
endometriosis diagnosis rather than before their diagnosis (78.8%
vs. 21.2%), even though we only considered migraines occurring
near the time period at which endometriosis was diagnosed, or
from 1 or 2 years before the endometriosis diagnosis date to 1 or 2
years after the end date. However, because of the longer mean
duration between endometriosis diagnoses and follow-up onsets of
migraines (after vs. before: 1,477 days vs. 490 days), the definition
of the time period would filter out more cases of migraines
occurring after the endometriosis diagnoses.
A number of aspects of the pathophysiological pathways
believed to underlie endometriosis may explain its apparent
relationship with migraine. For example, it has been proposed that
the activation of sensory fibers within ectopic endometrial tissue
(similar to an endometriosis lesion) can lead to neuronal
hyperactivity throughout the central nervous system [24]. This
phenomenon appears to be independent of nerve injury [25]. It is
also possible that an excessive number of activated and
degranulating mast cells within the endometriosis lesions or
internal nerve structures can induce the release of a host of
proinflammatory and algesic mediators. These mediators may
then sensitize primary afferent meningeal nociceptive neurons
Table 1. Demographic and clinical characteristics of endometriosis patients and controls.
Endometriosis (n=20,220) (%) Control (n=263,767) (%) P-value
Mean age (SD) 38.11 (8.325) 33.94 (9.557) ,0.001
Age (years)
#20 318 (1.6) 20,170 (7.6) ,0.001
21–30 4,029 (19.9) 88,358 (33.5)
31–40 6,745 (33.3) 77,410 (29.3)
41–50 8,534 (42.2) 71,255 (27.0)
$51 594 (2.9) 6,574 (2.5)
Infertility 3,003 (14.9) 12,773 (4.8) ,0.001
Pelvic pain 8,703 (43.0) 67,851 (25.7) ,0.001
Laparoscopic surgeries 4,277 (21.2) 4,476 (1.7) ,0.001
Danazol 1,863 (9.2) 1,556 (0.6) ,0.001
Estrogen (cream) 354 (1.8) 1,050 (0.4) ,0.001
Estrogen (tablet) 7,198 (35.6) 54,505 (20.7) ,0.001
Progestin (injection) 5,799 (28.7) 51,428 (19.5) ,0.001
Progestin (tablet) 9,717 (48.1) 68,330 (25.9) ,0.001
SD, standard deviation.
doi:10.1371/journal.pone.0033941.t001
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potentially trigger the migraine attacks [7].
Our results also showed endometriosis patients had significantly
greater hormone use than control subjects. Women with
endometriosis were more likely to have been treated with injected
or oral progestin than women without endometriosis. This finding
was not surprising since progestin is a well-documented treatment
in the management of endometriosis. In a similar vein, it was not
surprising that the percentage of women using danazol was higher
among those with endometriosis than among those without the
disease. Although prescribed estrogen has been implicated in the
pathogenesis of endometriosis, it is possible that the patients in our
study may have been treated with this hormone for menorrhagia,
dysmenorrhea or other health problems. In addition, transient
menopause, a potential side effect of endometriosis therapy, is
frequently treated with a hormone regimen consisting of estrogen.
Estrogen and other hormonal treatments have been shown to
trigger migraines and migraine-related aura [28]. Consequently,
migraine has been reported as an adverse side effect of estrogen
use [29]. Oral estrogen can also worsen the headaches in
postmenopausal migraine sufferers [30]. Endogenous variations
in female hormone levels associated with the menstrual cycle and
menstruation have also been shown to contribute to migraines
[31,32,33]. Thus, it is reasonable to conclude that hormones
prescribed for the treatment of endometriosis may influence the
onset and severity of migraines. In the current study, a greater
proportion of patients in the danazol medication group suffered
from migraines than patients without this medication (OR=1.36;
after controlling for diagnoses of endometriosis). A similar
association was observed under other hormone therapy conditions.
However, differences in administration routes or types of female
hormones may contribute to the conflicting results among studies.
Changing the type of hormone or route of admission, such as
switching to transdermal estrogen, is recommended if migraines
occur as a side effect of hormone treatment [29]. The results of the
current study did not support the protective effect of estrogen
cream against migraine, but it would be difficult to reach a
conclusion due to the small number of women in this hormonal
group.
Our data demonstrated that endometriosis is still an indepen-
dent predictor of migraine (OR=1.37), after adjustment of
hormone medications. Since patients with endometriosis had a
higher probability of being treated with hormones, and both
migraines and hormone therapy are associated with a higher
incidence of cardiovascular disease [34,35], we recommend that
physicians screen endometriosis patients for migraines before
prescribing hormone therapy. Although the use of female
hormone therapies is associated with a higher risk for migraines,
additional studies are needed to determine if this is a causal
relationship.
The strengths of the current study include the use of a large
population-based medical claims dataset, the inclusion of hormone
treatments as a variable, and the independent regression models;
however, we also acknowledge that this study had several
limitations. First, the disease diagnoses were coded according to
the ICD9-CM (for example, 346.0x, 346.1x, and 346.9x for
migraine, and 617.x for endometriosis) and obtained from
administrative claims reported by hospitals or clinics, which may
be considered less accurate than clinical diagnoses by standard
criteria. According to a prior survey [36], only 21.2% of
endometriosis patients had surgical validation of the disease, and
physicians in the outpatient clinic failed to appropriately diagnose
approximately 23% of migraine sufferers. Furthermore a preva-
lence of 12% was shown in a subset of asymptomatic patients
indicated for sterilization, and the overall prevalence among the
women undergoing laparoscopy was 32.5% [37]. Nevertheless, a
small proportion of subjects might have been under-diagnosed or
misdiagnosed, and this constitutes a limitation of the current study.
Despite these potential drawbacks, the data remain representative,
as the Bureau of NHI routinely and randomly sampled a fixed
percentage of claims from every contracted medical institution.
Moreover, an independent group of physicians and gynecologists
reviewed the charts and validated the diagnoses of endometriosis
and migraines. Furthermore, the migraine diagnosis did not
interfere with the endometriosis diagnosis and vice versa. Although
headaches may be a side effect of hormone treatment used for
endometriosis, as supported by our observation that 78.8% of
migraines occurred following the diagnosis of endometriosis, our
study still found that the prevalence of migraines was 37% higher
in endometriosis patients (95% CI=1.27,1.47), even after
adjusting for hormone therapies. Therefore, the potential for
diagnostic deviation failed to influence the co-morbid relationship
between endometriosis and migraines. A second limitation of the
current study may be patient compliance. For example, medical
Table 2. Odds ratio values of migraine, including independent variables.
Independent variable Odds ratio 95% CI P-value
Model 1: Adjusted for age, diagnoses of infertility and pelvic pain, and treatments of laparoscopic surgeries
Endometriosis 1.36 1.26–1.46 ,0.001
Infertility 1.16 1.07–1.27 0.001
Pelvic pain 1.88 1.80–1.96 ,0.001
Laparoscopic surgeries 1.11 0.99–1.24 0.065
Model 2: Adjusted for age, and danazol, estrogen, and progestin medications
Endometriosis 1.37 1.27–1.47 ,0.001
Danazol 1.36 1.16–1.58 ,0.001
Estrogen (cream) 1.61 1.30–1.98 ,0.001
Estrogen (oral) 1.27 1.21–1.34 ,0.001
Progestin (injection) 1.23 1.17–1.30 ,0.001
Progestin (oral) 1.31 1.24–1.37 ,0.001
CI, confidence interval.
doi:10.1371/journal.pone.0033941.t002
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drugs) does not verify that the drugs were actually taken by the
patient. Therefore, our results may have underestimated the effects
of medication on our subjects. Third, the administrative claims
data from the NHIRD did not include detailed personal
information (e.g., body mass index, living habits, or laboratory
test results), which may add confounding factors to the relation of
migraine or endometriosis. Fourth, the prevalence of migraines in
this cohort was 3.1%, which is much lower than the 14.4%
estimated prevalence for the community [13]. A previous study
suggested that many patients with migraines fail to seek medical
help [38], which may explain the discrepancy in our findings.
Nonetheless, we should use caution when applying our conclusions
to the community population as a whole. Fifth, we did not control
all the potential risk factors of endometriosis and migraine which
might influence their co-morbidities. A final limitation of our study
pertains to the treatments used for women diagnosed with
endometriosis. Transient menopause is a common consequence
of the management of endometriosis and is triggered either by the
surgical ablation of the ovarian function or the use of menopause-
inducing medications, such as gonadotropin releasing hormone
(GnRH) agonist. Unfortunately, we were unable to determine
whether the patients in our study were being treated with GnRH,
as the NHI Bureau did not cover this prescription.
In conclusion, the results of this population-based cohort study
support the existence of a co-morbid relationship between
migraine and endometriosis. This co-morbid association exists
after adjusting the influences of pelvic pain symptoms or hormone
therapies on migraine. Although endometriosis is associated with a
higher risk of migraines, additional studies are needed to delineate
the pathophysiological pathways underlying this co-morbid
relationship.
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